[Clinical profile and management of patients with neuropathic pain treated with pregabalin in rehabilitation clinics in Spain: the PRELURE cross-sectional survey].
de Miguel Benadiba C C, Ambrós Helena Bascuñana HB
To describe the clinical profile and management of patients with neuropathic pain referred for the first time to Physical Medicine and Rehabilitation clinics in Spain, as well as the use of pregabalin. A descriptive, nationwide survey based on aggregated data obtained through an online questionnaire. Each participant provided information on their last 6 patients with neuropathic pain referred for the first time and prescribed pregabalin at the consultation. A total of 124 specialists participated. Among their patients, chronic pain predominated (100.0%; Q1-Q3: 66.7-100.0), with a median duration of 8 months, as did mixed neuropathic-nociceptive pain (66.7%; Q1-Q3: 33.3-100.0). Baseline pain intensity (0-10) was high, with a mean score of 7.2 (SD 1.2) in women and 6.8 (SD 1.0) in men. Functional impairment, sleep and mood impairment were frequent. Before referral, pregabalin use was limited, with a mean initial dose of 104.9 (SD 65.7) mg/day in women and 130.5 (SD 110.8) mg/day in men. Following the consultation, the reported mean dose was 147.4 (SD 112.2) and 148.8 (SD 92.4) mg/day, respectively. Based on the physicians' retrospective estimates, at three months after treatmen adjustment, they perceived a reduction in the mean proportion of patients experiencing severe pain to 5.9% in women and 4.8% in men. Patients referred to Rehabilitation and treated with pregabalin present a high symptomatic and functional burden. Lower doses were observed before referral. After the consultation, treatment was adjusted and physicians perceived a reduction in patients with severe pain at three months.